Cable One, Inc. CABO 深 滬
已收盤 12-19 16:00:00 美东时间
127.09
-3.740
-2.86%
華盛通- 最 高131.12
- 今 開130.44
- 成交量 17.83万股
- 最 低 126.00
- 昨 收 130.83
- 總市值 7.15亿
- 52周最高 381.155
- 市盈率 靜 49.34
- 換手率 3.17%
- 52周最低 96.67
- 委 比 0.00%
- 總股本 562.90万
- 歷史最高 2278.75
- 量 比 1.03
- 振 幅 3.91%
- 歷史最低 96.67
- 每 手 1
- 風險率 75.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
11-27 04:13
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Wells Fargo Maintains Underweight on Cable One, Lowers Price Target to $107
Wells Fargo analyst Steven Cahall maintains Cable One (NYSE:CABO) with a Underweight and lowers the price target from $120 to $107.
11-08 03:05
Cable One Q3 EPS $14.52 Beats $6.39 Estimate, Sales $376.012M Miss $379.114M Estimate
Cable One (NYSE:CABO) reported quarterly earnings of $14.52 per share which beat the analyst consensus estimate of $6.39 by 127.3 percent. This is a 91.56 percent increase over earnings of $7.58 per share from the same
11-07 05:39
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Sirius XM Holdings Earnings Preview
Sirius XM Holdings (NASDAQ:SIRI) will release its quarterly earnings report on ...
10-30 03:02
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Cabaletta Bio announced positive clinical data for rese-cel in treating patients with myositis, systemic sclerosis (SSc), and lupus. In the Phase 1/2 DM/ASyS cohort, all patients meeting inclusion criteria achieved major clinical responses without immunomodulators. A registrational trial for DM/ASyS is planned with 14 patients and a 16-week endpoint. In SSc, all patients with sufficient follow-up showed transformative responses off immunomodulato...
10-27 11:00
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
Cabaletta Bio appoints Steve Gavel as Chief Commercial Officer, who brings extensive CAR T experience from Legend Biotech. Gavel will lead global commercial strategy for rese-cel, with a BLA submission expected in 2027. He previously led the successful launch of CARVYKTI® at Legend Biotech and has a strong track record in commercializing cell therapies. The company anticipates Gavel's leadership will enhance the commercialization efforts for rese...
10-14 12:00
